Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference

by B2i | Feb 7, 2022 | Press Releases

JUPITER, Fla., Feb. 07, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform...

Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process

by B2i | Jan 20, 2022 | Press Releases

JUPITER, Fla., Jan. 20, 2022 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...

Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan

by B2i | Dec 22, 2021 | Press Releases

JUPITER, Fla., Dec. 22, 2021 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...

Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform

by B2i | Dec 17, 2021 | Press Releases

JUPITER, Fla., Dec. 17, 2021 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and...

Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

by B2i | Nov 10, 2021 | Press Releases

•COVID-19 vaccine candidate, DYAI-100, continues to advance towards first-in-human clinical trial to validate C1 produced proteins are safe in humans and further accelerate global C1 platform adoption •Five non-COVID-19 infectious disease monoclonal...

Dyadic Appoints Chief Business Officer to Executive Leadership Team

by B2i | Nov 9, 2021 | Press Releases

JUPITER, Fla., Nov. 09, 2021 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...